Emcure Pharmaceuticals has opened its new formulation research and development (R&D) centre in Ahmedabad, in the Indian state of Gujarat.

The centre will focus on developing complex drug delivery systems such as sustained-release formulations, liposomal injections and advanced dermal therapies.

The facility, called the Emcure Research Centre (ERC), is equipped with modern laboratories and equipment for varying dosage forms.

The facility will incorporate every aspect of pharmaceutical development, from pre-formulation studies to scaling up, in compliance with global regulatory standards.

The facility will employ 350 skilled professionals, who will collaborate to develop new formulations, improve drug bioavailability and devise patient-centric delivery solutions.

ERC's research will span multiple dosage forms such as oral solid dosage, inhalers, injectables, novel drug delivery systems and topical and transdermal formulations.  

Emcure Pharmaceuticals founder and CEO Satish Mehta stated: “This new R&D centre represents a significant milestone in our continued pursuit of innovation, by combining advanced research technology with a talented team.

“With a focus on both efficiency and quality, the centre is set to drive advancements that will reshape the future of medicine globally.”

In October 2024, the company announced the formation of Emcutix Biopharmaceuticals, its wholly-owned subsidiary,  focusing on the dermatology sector.

Emcure's existing dermatology business operates under Emcutix as part of this strategic move.

In April 2021, Emcure Pharmaceuticals joined forces with MSD through a non-exclusive voluntary licensing agreement to expand access to the investigational oral COVID-19 drug, molnupiravir.

Alongside Emcure, Indian generics manufacturers Cipla, Dr Reddy’s Laboratories, Hetero Labs and Sun Pharmaceutical Industries have also signed agreements to boost the drug's supply in India.